aluates Reports

$ 0.0

Automative

Global Cancer Immuno Personalized Medicine Market Research Report 2026

Published Date: 2026-03-25

Report Code: QYRE-Auto-20O17332

Global Cancer Immuno Personalized Medicine Market Research Report 2024

BUY CHAPTERS

Global Cancer Immuno Personalized Medicine Market Research Report 2026

Code: QYRE-Auto-20O17332

Report

2026-03-25

Pages:121

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol–Myers Squibb

Amgen Inc

Astrazeneca plc

Merck

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer Inc

GSK

Exelixis Inc

Regeneron

Innovent

Hengrui Medicine

Johnson & Johnson

Cancer Immuno Personalized Medicine Market

The global Cancer Immuno Personalized Medicine market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight diseases, particularly cancer. Unlike traditional treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy stimulates the body's natural defenses to identify and destroy cancer cells more effectively. It is a type of personalized treatment. (Immunotherapy is often tailored to the patient's specific cancer and immune system. Biomarker testing is sometimes performed to determine the suitability of certain immunotherapy drugs.)

The North American market for Cancer Immuno Personalized Medicine is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Cancer Immuno Personalized Medicine is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Cancer Immuno Personalized Medicine in Lung Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Cancer Immuno Personalized Medicine include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Cancer Immuno Personalized Medicine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Immuno Personalized Medicine. The Cancer Immuno Personalized Medicine market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Cancer Immuno Personalized Medicine market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Cancer Immuno Personalized Medicine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Cancer Immuno Personalized Medicine Market Report

Report Metric	Details
Report Name	Cancer Immuno Personalized Medicine Market
Segment by Type	Immune Checkpoint Inhibitors Cytokine-Based Immunotherapy CAR-T Cell Therapy Other
Segment by Application	Lung Cancer Breast Cancer Prostate Cancer Blood-related Cancer Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Cancer Immuno Personalized Medicine companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Cancer Immuno Personalized Medicine Market report?

Ans: The main players in the Cancer Immuno Personalized Medicine Market are AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine

What are the Application segmentation covered in the Cancer Immuno Personalized Medicine Market report?

Ans: The Applications covered in the Cancer Immuno Personalized Medicine Market report are Lung Cancer, Breast Cancer, Prostate Cancer, Blood-related Cancer, Other

What are the Type segmentation covered in the Cancer Immuno Personalized Medicine Market report?

Ans: The Types covered in the Cancer Immuno Personalized Medicine Market report are Immune Checkpoint Inhibitors, Cytokine-Based Immunotherapy, CAR-T Cell Therapy, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cancer Immuno Personalized Medicine Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Immune Checkpoint Inhibitors

1.2.3 Cytokine-Based Immunotherapy

1.2.4 CAR-T Cell Therapy

1.2.5 Other

1.3 Market by Application

1.3.1 Global Cancer Immuno Personalized Medicine Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Lung Cancer

1.3.3 Breast Cancer

1.3.4 Prostate Cancer

1.3.5 Blood-related Cancer

1.3.6 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Cancer Immuno Personalized Medicine Market Perspective (2021–2032)

2.2 Global Cancer Immuno Personalized Medicine Growth Trends by Region

2.2.1 Global Cancer Immuno Personalized Medicine Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Cancer Immuno Personalized Medicine Historic Market Size by Region (2021–2026)

2.2.3 Cancer Immuno Personalized Medicine Forecasted Market Size by Region (2027–2032)

2.3 Cancer Immuno Personalized Medicine Market Dynamics

2.3.1 Cancer Immuno Personalized Medicine Industry Trends

2.3.2 Cancer Immuno Personalized Medicine Market Drivers

2.3.3 Cancer Immuno Personalized Medicine Market Challenges

2.3.4 Cancer Immuno Personalized Medicine Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Cancer Immuno Personalized Medicine Players by Revenue

3.1.1 Global Top Cancer Immuno Personalized Medicine Players by Revenue (2021–2026)

3.1.2 Global Cancer Immuno Personalized Medicine Revenue Market Share by Players (2021–2026)

3.2 Global Top Cancer Immuno Personalized Medicine Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Cancer Immuno Personalized Medicine Revenue

3.4 Global Cancer Immuno Personalized Medicine Market Concentration Ratio

3.4.1 Global Cancer Immuno Personalized Medicine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cancer Immuno Personalized Medicine Revenue in 2025

3.5 Global Key Players of Cancer Immuno Personalized Medicine Head Offices and Areas Served

3.6 Global Key Players of Cancer Immuno Personalized Medicine, Products and Applications

3.7 Global Key Players of Cancer Immuno Personalized Medicine, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Cancer Immuno Personalized Medicine Breakdown Data by Type

4.1 Global Cancer Immuno Personalized Medicine Historic Market Size by Type (2021–2026)

4.2 Global Cancer Immuno Personalized Medicine Forecasted Market Size by Type (2027–2032)

5 Cancer Immuno Personalized Medicine Breakdown Data by Application

5.1 Global Cancer Immuno Personalized Medicine Historic Market Size by Application (2021–2026)

5.2 Global Cancer Immuno Personalized Medicine Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Cancer Immuno Personalized Medicine Market Size (2021–2032)

6.2 North America Cancer Immuno Personalized Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Cancer Immuno Personalized Medicine Market Size by Country (2021–2026)

6.4 North America Cancer Immuno Personalized Medicine Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Cancer Immuno Personalized Medicine Market Size (2021–2032)

7.2 Europe Cancer Immuno Personalized Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Cancer Immuno Personalized Medicine Market Size by Country (2021–2026)

7.4 Europe Cancer Immuno Personalized Medicine Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Cancer Immuno Personalized Medicine Market Size (2021–2032)

8.2 Asia-Pacific Cancer Immuno Personalized Medicine Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Cancer Immuno Personalized Medicine Market Size by Region (2021–2026)

8.4 Asia-Pacific Cancer Immuno Personalized Medicine Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Cancer Immuno Personalized Medicine Market Size (2021–2032)

9.2 Latin America Cancer Immuno Personalized Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Cancer Immuno Personalized Medicine Market Size by Country (2021–2026)

9.4 Latin America Cancer Immuno Personalized Medicine Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Cancer Immuno Personalized Medicine Market Size (2021–2032)

10.2 Middle East & Africa Cancer Immuno Personalized Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Cancer Immuno Personalized Medicine Market Size by Country (2021–2026)

10.4 Middle East & Africa Cancer Immuno Personalized Medicine Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AbbVie

11.1.1 AbbVie Company Details

11.1.2 AbbVie Business Overview

11.1.3 AbbVie Cancer Immuno Personalized Medicine Introduction

11.1.4 AbbVie Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.1.5 AbbVie Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Details

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Cancer Immuno Personalized Medicine Introduction

11.2.4 Johnson & Johnson Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.2.5 Johnson & Johnson Recent Development

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis Cancer Immuno Personalized Medicine Introduction

11.3.4 Novartis Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.3.5 Novartis Recent Development

11.4 Gilead Sciences

11.4.1 Gilead Sciences Company Details

11.4.2 Gilead Sciences Business Overview

11.4.3 Gilead Sciences Cancer Immuno Personalized Medicine Introduction

11.4.4 Gilead Sciences Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.4.5 Gilead Sciences Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Cancer Immuno Personalized Medicine Introduction

11.5.4 Roche Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.5.5 Roche Recent Development

11.6 Bristol-Myers Squibb

11.6.1 Bristol-Myers Squibb Company Details

11.6.2 Bristol-Myers Squibb Business Overview

11.6.3 Bristol-Myers Squibb Cancer Immuno Personalized Medicine Introduction

11.6.4 Bristol-Myers Squibb Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.6.5 Bristol-Myers Squibb Recent Development

11.7 Amgen

11.7.1 Amgen Company Details

11.7.2 Amgen Business Overview

11.7.3 Amgen Cancer Immuno Personalized Medicine Introduction

11.7.4 Amgen Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.7.5 Amgen Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Cancer Immuno Personalized Medicine Introduction

11.8.4 AstraZeneca Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.8.5 AstraZeneca Recent Development

11.9 Merck & Co

11.9.1 Merck & Co Company Details

11.9.2 Merck & Co Business Overview

11.9.3 Merck & Co Cancer Immuno Personalized Medicine Introduction

11.9.4 Merck & Co Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.9.5 Merck & Co Recent Development

11.10 Takeda

11.10.1 Takeda Company Details

11.10.2 Takeda Business Overview

11.10.3 Takeda Cancer Immuno Personalized Medicine Introduction

11.10.4 Takeda Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.10.5 Takeda Recent Development

11.11 Merck KGaA

11.11.1 Merck KGaA Company Details

11.11.2 Merck KGaA Business Overview

11.11.3 Merck KGaA Cancer Immuno Personalized Medicine Introduction

11.11.4 Merck KGaA Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.11.5 Merck KGaA Recent Development

11.12 Seagen

11.12.1 Seagen Company Details

11.12.2 Seagen Business Overview

11.12.3 Seagen Cancer Immuno Personalized Medicine Introduction

11.12.4 Seagen Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.12.5 Seagen Recent Development

11.13 Eli Lilly

11.13.1 Eli Lilly Company Details

11.13.2 Eli Lilly Business Overview

11.13.3 Eli Lilly Cancer Immuno Personalized Medicine Introduction

11.13.4 Eli Lilly Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.13.5 Eli Lilly Recent Development

11.14 Ono Pharmaceutical

11.14.1 Ono Pharmaceutical Company Details

11.14.2 Ono Pharmaceutical Business Overview

11.14.3 Ono Pharmaceutical Cancer Immuno Personalized Medicine Introduction

11.14.4 Ono Pharmaceutical Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.14.5 Ono Pharmaceutical Recent Development

11.15 Pfizer

11.15.1 Pfizer Company Details

11.15.2 Pfizer Business Overview

11.15.3 Pfizer Cancer Immuno Personalized Medicine Introduction

11.15.4 Pfizer Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.15.5 Pfizer Recent Development

11.16 GSK

11.16.1 GSK Company Details

11.16.2 GSK Business Overview

11.16.3 GSK Cancer Immuno Personalized Medicine Introduction

11.16.4 GSK Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.16.5 GSK Recent Development

11.17 Exelixis

11.17.1 Exelixis Company Details

11.17.2 Exelixis Business Overview

11.17.3 Exelixis Cancer Immuno Personalized Medicine Introduction

11.17.4 Exelixis Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.17.5 Exelixis Recent Development

11.18 Regeneron

11.18.1 Regeneron Company Details

11.18.2 Regeneron Business Overview

11.18.3 Regeneron Cancer Immuno Personalized Medicine Introduction

11.18.4 Regeneron Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.18.5 Regeneron Recent Development

11.19 Innovent

11.19.1 Innovent Company Details

11.19.2 Innovent Business Overview

11.19.3 Innovent Cancer Immuno Personalized Medicine Introduction

11.19.4 Innovent Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.19.5 Innovent Recent Development

11.20 Hengrui Medicine

11.20.1 Hengrui Medicine Company Details

11.20.2 Hengrui Medicine Business Overview

11.20.3 Hengrui Medicine Cancer Immuno Personalized Medicine Introduction

11.20.4 Hengrui Medicine Revenue in Cancer Immuno Personalized Medicine Business (2021–2026)

11.20.5 Hengrui Medicine Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

AbbVie

Johnson & Johnson

Novartis

Gilead Sciences

Roche

Bristol–Myers Squibb

Amgen Inc

Astrazeneca plc

Merck

Takeda

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer Inc

GSK

Exelixis Inc

Regeneron

Innovent

Hengrui Medicine

Johnson & Johnson

List of Tables

Table 1. Global Cancer Immuno Personalized Medicine Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Immune Checkpoint Inhibitors

Table 3. Key Players of Cytokine-Based Immunotherapy

Table 4. Key Players of CAR-T Cell Therapy

Table 5. Key Players of Other

Table 6. Global Cancer Immuno Personalized Medicine Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Cancer Immuno Personalized Medicine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global Cancer Immuno Personalized Medicine Market Size by Region (US$ Million), 2021–2026

Table 9. Global Cancer Immuno Personalized Medicine Market Share by Region (2021–2026)

Table 10. Global Cancer Immuno Personalized Medicine Forecasted Market Size by Region (US$ Million), 2027–2032

Table 11. Global Cancer Immuno Personalized Medicine Market Share by Region (2027–2032)

Table 12. Cancer Immuno Personalized Medicine Market Trends

Table 13. Cancer Immuno Personalized Medicine Market Drivers

Table 14. Cancer Immuno Personalized Medicine Market Challenges

Table 15. Cancer Immuno Personalized Medicine Market Restraints

Table 16. Global Cancer Immuno Personalized Medicine Revenue by Players (US$ Million), 2021–2026

Table 17. Global Cancer Immuno Personalized Medicine Market Share by Players (2021–2026)

Table 18. Global Top Cancer Immuno Personalized Medicine Players by Tier (Tier 1, Tier 2, and Tier 3), based on Cancer Immuno Personalized Medicine Revenue, 2025

Table 19. Ranking of Global Top Cancer Immuno Personalized Medicine Companies by Revenue (US$ Million) in 2025

Table 20. Global 5 Largest Players Market Share by Cancer Immuno Personalized Medicine Revenue (CR5 and HHI), 2021–2026

Table 21. Global Key Players of Cancer Immuno Personalized Medicine, Headquarters and Area Served

Table 22. Global Key Players of Cancer Immuno Personalized Medicine, Products and Applications

Table 23. Global Key Players of Cancer Immuno Personalized Medicine, Date of General Availability (GA)

Table 24. Mergers and Acquisitions, Expansion Plans

Table 25. Global Cancer Immuno Personalized Medicine Market Size by Type (US$ Million), 2021–2026

Table 26. Global Cancer Immuno Personalized Medicine Revenue Market Share by Type (2021–2026)

Table 27. Global Cancer Immuno Personalized Medicine Forecasted Market Size by Type (US$ Million), 2027–2032

Table 28. Global Cancer Immuno Personalized Medicine Revenue Market Share by Type (2027–2032)

Table 29. Global Cancer Immuno Personalized Medicine Market Size by Application (US$ Million), 2021–2026

Table 30. Global Cancer Immuno Personalized Medicine Revenue Market Share by Application (2021–2026)

Table 31. Global Cancer Immuno Personalized Medicine Forecasted Market Size by Application (US$ Million), 2027–2032

Table 32. Global Cancer Immuno Personalized Medicine Revenue Market Share by Application (2027–2032)

Table 33. North America Cancer Immuno Personalized Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 34. North America Cancer Immuno Personalized Medicine Market Size by Country (US$ Million), 2021–2026

Table 35. North America Cancer Immuno Personalized Medicine Market Size by Country (US$ Million), 2027–2032

Table 36. Europe Cancer Immuno Personalized Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 37. Europe Cancer Immuno Personalized Medicine Market Size by Country (US$ Million), 2021–2026

Table 38. Europe Cancer Immuno Personalized Medicine Market Size by Country (US$ Million), 2027–2032

Table 39. Asia-Pacific Cancer Immuno Personalized Medicine Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 40. Asia-Pacific Cancer Immuno Personalized Medicine Market Size by Region (US$ Million), 2021–2026

Table 41. Asia-Pacific Cancer Immuno Personalized Medicine Market Size by Region (US$ Million), 2027–2032

Table 42. Latin America Cancer Immuno Personalized Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. Latin America Cancer Immuno Personalized Medicine Market Size by Country (US$ Million), 2021–2026

Table 44. Latin America Cancer Immuno Personalized Medicine Market Size by Country (US$ Million), 2027–2032

Table 45. Middle East & Africa Cancer Immuno Personalized Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Middle East & Africa Cancer Immuno Personalized Medicine Market Size by Country (US$ Million), 2021–2026

Table 47. Middle East & Africa Cancer Immuno Personalized Medicine Market Size by Country (US$ Million), 2027–2032

Table 48. AbbVie Company Details

Table 49. AbbVie Business Overview

Table 50. AbbVie Cancer Immuno Personalized Medicine Product

Table 51. AbbVie Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 52. AbbVie Recent Development

Table 53. Johnson & Johnson Company Details

Table 54. Johnson & Johnson Business Overview

Table 55. Johnson & Johnson Cancer Immuno Personalized Medicine Product

Table 56. Johnson & Johnson Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 57. Johnson & Johnson Recent Development

Table 58. Novartis Company Details

Table 59. Novartis Business Overview

Table 60. Novartis Cancer Immuno Personalized Medicine Product

Table 61. Novartis Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 62. Novartis Recent Development

Table 63. Gilead Sciences Company Details

Table 64. Gilead Sciences Business Overview

Table 65. Gilead Sciences Cancer Immuno Personalized Medicine Product

Table 66. Gilead Sciences Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 67. Gilead Sciences Recent Development

Table 68. Roche Company Details

Table 69. Roche Business Overview

Table 70. Roche Cancer Immuno Personalized Medicine Product

Table 71. Roche Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 72. Roche Recent Development

Table 73. Bristol-Myers Squibb Company Details

Table 74. Bristol-Myers Squibb Business Overview

Table 75. Bristol-Myers Squibb Cancer Immuno Personalized Medicine Product

Table 76. Bristol-Myers Squibb Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 77. Bristol-Myers Squibb Recent Development

Table 78. Amgen Company Details

Table 79. Amgen Business Overview

Table 80. Amgen Cancer Immuno Personalized Medicine Product

Table 81. Amgen Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 82. Amgen Recent Development

Table 83. AstraZeneca Company Details

Table 84. AstraZeneca Business Overview

Table 85. AstraZeneca Cancer Immuno Personalized Medicine Product

Table 86. AstraZeneca Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 87. AstraZeneca Recent Development

Table 88. Merck & Co Company Details

Table 89. Merck & Co Business Overview

Table 90. Merck & Co Cancer Immuno Personalized Medicine Product

Table 91. Merck & Co Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 92. Merck & Co Recent Development

Table 93. Takeda Company Details

Table 94. Takeda Business Overview

Table 95. Takeda Cancer Immuno Personalized Medicine Product

Table 96. Takeda Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 97. Takeda Recent Development

Table 98. Merck KGaA Company Details

Table 99. Merck KGaA Business Overview

Table 100. Merck KGaA Cancer Immuno Personalized Medicine Product

Table 101. Merck KGaA Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 102. Merck KGaA Recent Development

Table 103. Seagen Company Details

Table 104. Seagen Business Overview

Table 105. Seagen Cancer Immuno Personalized Medicine Product

Table 106. Seagen Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 107. Seagen Recent Development

Table 108. Eli Lilly Company Details

Table 109. Eli Lilly Business Overview

Table 110. Eli Lilly Cancer Immuno Personalized Medicine Product

Table 111. Eli Lilly Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 112. Eli Lilly Recent Development

Table 113. Ono Pharmaceutical Company Details

Table 114. Ono Pharmaceutical Business Overview

Table 115. Ono Pharmaceutical Cancer Immuno Personalized Medicine Product

Table 116. Ono Pharmaceutical Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 117. Ono Pharmaceutical Recent Development

Table 118. Pfizer Company Details

Table 119. Pfizer Business Overview

Table 120. Pfizer Cancer Immuno Personalized Medicine Product

Table 121. Pfizer Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 122. Pfizer Recent Development

Table 123. GSK Company Details

Table 124. GSK Business Overview

Table 125. GSK Cancer Immuno Personalized Medicine Product

Table 126. GSK Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 127. GSK Recent Development

Table 128. Exelixis Company Details

Table 129. Exelixis Business Overview

Table 130. Exelixis Cancer Immuno Personalized Medicine Product

Table 131. Exelixis Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 132. Exelixis Recent Development

Table 133. Regeneron Company Details

Table 134. Regeneron Business Overview

Table 135. Regeneron Cancer Immuno Personalized Medicine Product

Table 136. Regeneron Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 137. Regeneron Recent Development

Table 138. Innovent Company Details

Table 139. Innovent Business Overview

Table 140. Innovent Cancer Immuno Personalized Medicine Product

Table 141. Innovent Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 142. Innovent Recent Development

Table 143. Hengrui Medicine Company Details

Table 144. Hengrui Medicine Business Overview

Table 145. Hengrui Medicine Cancer Immuno Personalized Medicine Product

Table 146. Hengrui Medicine Revenue in Cancer Immuno Personalized Medicine Business (US$ Million), 2021–2026

Table 147. Hengrui Medicine Recent Development

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

Table 151. Authors List of This Report

List of Figures

Figure 1. Cancer Immuno Personalized Medicine Picture

Figure 2. Global Cancer Immuno Personalized Medicine Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Cancer Immuno Personalized Medicine Market Share by Type: 2025 vs 2032

Figure 4. Immune Checkpoint Inhibitors Features

Figure 5. Cytokine-Based Immunotherapy Features

Figure 6. CAR-T Cell Therapy Features

Figure 7. Other Features

Figure 8. Global Cancer Immuno Personalized Medicine Market Size by Application (US$ Million), 2021–2032

Figure 9. Global Cancer Immuno Personalized Medicine Market Share by Application: 2025 vs 2032

Figure 10. Lung Cancer Case Studies

Figure 11. Breast Cancer Case Studies

Figure 12. Prostate Cancer Case Studies

Figure 13. Blood-related Cancer Case Studies

Figure 14. Other Case Studies

Figure 15. Cancer Immuno Personalized Medicine Report Years Considered

Figure 16. Global Cancer Immuno Personalized Medicine Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 17. Global Cancer Immuno Personalized Medicine Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 18. Global Cancer Immuno Personalized Medicine Market Share by Region: 2025 vs 2032

Figure 19. Global Cancer Immuno Personalized Medicine Market Share by Players in 2025

Figure 20. Global Cancer Immuno Personalized Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 21. The Top 10 and 5 Players Market Share by Cancer Immuno Personalized Medicine Revenue in 2025

Figure 22. North America Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. North America Cancer Immuno Personalized Medicine Market Share by Country (2021–2032)

Figure 24. United States Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Canada Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. Europe Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Europe Cancer Immuno Personalized Medicine Market Share by Country (2021–2032)

Figure 28. Germany Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. France Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. U.K. Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Italy Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Russia Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Ireland Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Asia-Pacific Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Asia-Pacific Cancer Immuno Personalized Medicine Market Share by Region (2021–2032)

Figure 36. China Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Japan Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. South Korea Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Southeast Asia Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. India Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Australia & New Zealand Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Latin America Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Latin America Cancer Immuno Personalized Medicine Market Share by Country (2021–2032)

Figure 44. Mexico Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Brazil Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Middle East & Africa Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Middle East & Africa Cancer Immuno Personalized Medicine Market Share by Country (2021–2032)

Figure 48. Israel Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Saudi Arabia Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. UAE Cancer Immuno Personalized Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. AbbVie Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 52. Johnson & Johnson Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 53. Novartis Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 54. Gilead Sciences Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 55. Roche Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 57. Amgen Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 58. AstraZeneca Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 59. Merck & Co Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 60. Takeda Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 61. Merck KGaA Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 62. Seagen Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 63. Eli Lilly Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 64. Ono Pharmaceutical Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 65. Pfizer Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 66. GSK Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 67. Exelixis Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 68. Regeneron Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 69. Innovent Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 70. Hengrui Medicine Revenue Growth Rate in Cancer Immuno Personalized Medicine Business (2021–2026)

Figure 71. Bottom-up and Top-down Approaches for This Report

Figure 72. Data Triangulation

Figure 73. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Cancer Immunosuppressant Treatment Market Research Report 2024

Global Immunosuppressants in Cancer Therapy Market Research Report 2024

Global Immunotherapy Drugs Market Research Report 2024

Immuno oncology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Immunotherapeutic Drugs Market Insights Forecast to 2030

Global Immuno oncology Therapy Market Insights Forecast to 2030

Global Cancer Immunotherapy Market Insights Forecast to 2030

Global Cancer Immunotherapies Market Insights Forecast to 2030

Global Cell Immunotherapy Platform Market Research Report 2024

Global CAR T Cell Immunotherapy Market Insights Forecast to 2030

Cancer Immunotherapy Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global TCR T Cellular Immunotherapy Market Research Report 2024

Global T Cell Immunotherapy Market Research Report 2025

Global Tumor Immune Cell Therapy Market Research Report 2024

Global Immuno Oncology Service Market Research Report 2024

Oncology Immunotherapy Market

Immune Cell Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Personalized Cancer Medicine Market Research Report 2025

Global Cancer Biotherapy Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions